Cogstate Limited Q4 2026 Earnings Recap

Cogstate shares declined 2.5% post-earnings as investors appeared cautious despite solid revenue growth and expanding contracted sales, likely reflecting concerns over margin pressure and the company's cautious outlook on FY '27 revenue conversion.

Key Takeaways

• Revenue for FY '26 rose 15% to just under $61 million, with profit before tax increasing 16%; however, gross margins declined slightly from 61% to 58% over the year due to investments in ramping trial capacity.
• Second half performance was notably stronger, with revenue up 27% versus first half and EBIT margins improving from 24% to 35%, indicating operating leverage benefit from higher volumes.
• Contracted future revenue reached a record $118.5 million as of June 2026, up 54% year-over-year, providing good visibility into FY '27, though management emphasized that actual revenue growth depends on successful conversion of these contracts.
• Trial starts nearly tripled to 90 in FY '26, with increased diversification across neurological areas beyond Alzheimer’s, supporting longer-term growth potential.
• Despite strong top-line momentum and an active share buyback, margin compression and a cautious tone around contract conversion likely weighed on investor sentiment, limiting upside in the stock.